IS2834B - Aðferðir til þess að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4-sameind - Google Patents
Aðferðir til þess að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4-sameindInfo
- Publication number
- IS2834B IS2834B IS6667A IS6667A IS2834B IS 2834 B IS2834 B IS 2834B IS 6667 A IS6667 A IS 6667A IS 6667 A IS6667 A IS 6667A IS 2834 B IS2834 B IS 2834B
- Authority
- IS
- Iceland
- Prior art keywords
- sameindáá
- amea
- treating
- transplant rejection
- disorder associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21591300P | 2000-07-03 | 2000-07-03 | |
PCT/US2001/021204 WO2002002638A2 (en) | 2000-07-03 | 2001-07-02 | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6667A IS6667A (is) | 2003-01-02 |
IS2834B true IS2834B (is) | 2013-05-15 |
Family
ID=22804919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6667A IS2834B (is) | 2000-07-03 | 2003-01-02 | Aðferðir til þess að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4-sameind |
Country Status (39)
Country | Link |
---|---|
US (1) | US7455835B2 (is) |
EP (4) | EP3384924A1 (is) |
JP (1) | JP2004517806A (is) |
KR (3) | KR100895552B1 (is) |
CN (1) | CN1318086C (is) |
AR (2) | AR035037A1 (is) |
AT (1) | ATE401909T1 (is) |
AU (2) | AU7317401A (is) |
BG (2) | BG66024B1 (is) |
BR (1) | BR0112104A (is) |
CA (2) | CA2413190C (is) |
CY (3) | CY1109786T1 (is) |
CZ (1) | CZ303959B6 (is) |
DE (1) | DE60135029D1 (is) |
DK (2) | DK1372696T3 (is) |
EE (1) | EE05378B1 (is) |
ES (2) | ES2667203T3 (is) |
HK (1) | HK1058486A1 (is) |
HR (1) | HRP20030071B1 (is) |
HU (3) | HU227669B1 (is) |
IL (2) | IL153593A0 (is) |
IS (1) | IS2834B (is) |
LT (2) | LT1935427T (is) |
LV (1) | LV12993B (is) |
MX (1) | MXPA02012603A (is) |
MY (1) | MY137552A (is) |
NO (3) | NO20026264L (is) |
PE (1) | PE20020772A1 (is) |
PL (2) | PL207534B1 (is) |
PT (2) | PT1372696E (is) |
RS (1) | RS50811B (is) |
RU (1) | RU2287340C2 (is) |
SI (3) | SI21078A (is) |
SK (1) | SK287940B6 (is) |
TR (1) | TR201807700T4 (is) |
TW (2) | TWI311564B (is) |
UY (1) | UY26815A1 (is) |
WO (1) | WO2002002638A2 (is) |
ZA (1) | ZA200210058B (is) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US6887471B1 (en) | 1991-06-27 | 2005-05-03 | Bristol-Myers Squibb Company | Method to inhibit T cell interactions with soluble B7 |
WO1997034633A1 (en) * | 1996-03-20 | 1997-09-25 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
DK1248802T3 (da) * | 2000-05-26 | 2004-11-15 | Bristol Myers Squibb Co | Oplöselige CTLA4-mutantmolekyler og anvendelser deraf |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
TWI311564B (en) * | 2000-07-03 | 2009-07-01 | Bristol Myers Squibb Compan | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
HUP0303930A3 (en) * | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
DK1397153T3 (da) | 2001-05-23 | 2008-05-26 | Bristol Myers Squibb Co | Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler |
CA2482042A1 (en) * | 2002-04-19 | 2003-10-30 | Bristol-Myers Squibb Company | Methods for treating an autoimmune disease using a soluble ctla4 molecule and a dmard or nsaid |
CN100402660C (zh) * | 2002-12-23 | 2008-07-16 | 布里斯托尔-迈尔斯斯奎布公司 | 用于蛋白质生产的哺乳动物细胞培养方法中产物质量提高 |
WO2004058800A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
MXPA05007019A (es) | 2002-12-30 | 2005-08-18 | Amgen Inc | Terapia de combinacion con factores co-estimuladores. |
WO2005016266A2 (en) * | 2003-08-04 | 2005-02-24 | Bristol-Myers Squibb Company | Methods for treating cardiovascular disease using a soluble ctla4 molecule |
WO2005044188A2 (en) | 2003-10-27 | 2005-05-19 | Amgen Inc. | Compositions and methods to modulate an immune response to an immunogenic therapeutic agent |
US7815765B2 (en) * | 2004-04-01 | 2010-10-19 | Swei Mu Wang | Method for forming laminated synthetic leather |
AU2006330922B2 (en) | 2005-12-20 | 2012-07-26 | Bristol-Myers Squibb Company | Compositions and methods for producing a composition |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
AR058567A1 (es) * | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Formulaciones de proteinas estables |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
US7528111B2 (en) * | 2006-05-12 | 2009-05-05 | Bristol-Myers Squibb Company | Method of vaccinating subjects receiving immune modulating therapy |
GB0620934D0 (en) * | 2006-10-20 | 2006-11-29 | Cambridge Antibody Tech | Protein variants |
AU2014250683B2 (en) * | 2007-11-01 | 2015-11-26 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
AU2012202324B2 (en) * | 2007-11-01 | 2014-08-28 | Astellas Pharma Inc. | Immunosuppressive polypeptides and nucleic acids |
PL2222697T3 (pl) * | 2007-11-01 | 2013-05-31 | Astellas Pharma Inc | Immunosupresyjne polipeptydy i kwasy nukleinowe |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
EP2334234A4 (en) | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD |
US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
WO2010049935A1 (en) * | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
US9211377B2 (en) | 2009-07-30 | 2015-12-15 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
CN102030828B (zh) * | 2009-09-25 | 2014-10-29 | 上海抗体药物国家工程研究中心有限公司 | 一种高亲和力的CTLA4-Ig融合蛋白突变体 |
HUE030100T2 (en) * | 2010-02-19 | 2017-04-28 | Xencor Inc | New CTLA4-IG immunoadhesins |
CN106432474A (zh) * | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | Ctla4蛋白和其用途 |
WO2011146395A2 (en) | 2010-05-17 | 2011-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade |
MX357746B (es) | 2010-09-08 | 2018-07-23 | Yeda Res And Development Co Ltd Star | Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma. |
EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
WO2013010537A1 (en) * | 2011-07-20 | 2013-01-24 | Aarhus Universitet | Method of treating morphea |
US20140212398A1 (en) | 2011-09-08 | 2014-07-31 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US8735359B2 (en) | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
MX2015000237A (es) | 2012-06-27 | 2015-08-14 | Orban Biotech Llc | Proteinas de fusion ctla4 para el tratamiento de la diabetes. |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
WO2014151230A2 (en) | 2013-03-15 | 2014-09-25 | Bristol-Myers Squibb Company | Method of treating granulomatosis with polyangiitis |
CN104740608A (zh) * | 2013-12-30 | 2015-07-01 | 上海中信国健药业股份有限公司 | 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途 |
GB2523399B (en) | 2014-02-25 | 2019-03-13 | Orban Tihamer | A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence |
MX2016013611A (es) * | 2014-04-25 | 2017-02-02 | Bristol Myers Squibb Co | Uso del compuesto antigeno 4 del linfocito t toxico (ctla4) para lograr la remision libre de farmacos en sujetos con artritis reumatoide (ra) temprana. |
PT3283508T (pt) | 2015-04-17 | 2021-06-21 | Alpine Immune Sciences Inc | Proteínas imuno modulatórias com afinidades afináveis |
US10933124B2 (en) | 2015-07-16 | 2021-03-02 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
CN109715657A (zh) | 2016-04-15 | 2019-05-03 | 高山免疫科学股份有限公司 | Cd80变体免疫调节蛋白及其用途 |
US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
US11555178B2 (en) | 2017-01-18 | 2023-01-17 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
MA50360A (fr) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences Inc | Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations |
SG11202003078VA (en) | 2017-10-18 | 2020-05-28 | Alpine Immune Sciences Inc | Variant icos ligand immunomodulatory proteins and related compositions and methods |
WO2019175384A2 (en) | 2018-03-16 | 2019-09-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes |
US20210023209A1 (en) | 2018-03-16 | 2021-01-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes |
EP3765065A2 (en) | 2018-03-16 | 2021-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes |
US20220098264A1 (en) | 2019-01-15 | 2022-03-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy |
WO2023112992A1 (ja) * | 2021-12-16 | 2023-06-22 | レグセル株式会社 | 免疫系の異常に関連する疾患、障害または症状を処置するための医薬組成物 |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US644792A (en) * | 1899-09-14 | 1900-03-06 | Stanhope Boal | Heater. |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
DE3424893A1 (de) | 1984-07-06 | 1986-02-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Photographisches silberhalogenidaufzeichnungsmaterial |
US6352694B1 (en) * | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
CA2003455C (en) * | 1988-11-23 | 2000-02-22 | Craig B. Thompson | Immunotherapy involving cd28 stimulation |
US6685941B1 (en) * | 1988-11-23 | 2004-02-03 | The Regents Of The University Of Michigan | Methods of treating autoimmune disease via CTLA-4Ig |
US6905680B2 (en) * | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
US7070776B1 (en) * | 1990-03-26 | 2006-07-04 | Bristol-Myers Squibb Company | Methods for blocking binding of CD28 receptor to B7 |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US5770197A (en) | 1991-06-27 | 1998-06-23 | Bristol-Myers Squibb Company | Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules |
ATE170562T1 (de) * | 1991-06-27 | 1998-09-15 | Bristol Myers Squibb Co | Ctl4a rezeptor, ihn enthaltenden fusionsproteine und deren verwendungen |
US6090914A (en) | 1991-06-27 | 2000-07-18 | Bristol-Myers Squibb Company | CTLA4/CD28Ig hybrid fusion proteins and uses thereof |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
US5624823A (en) * | 1991-11-22 | 1997-04-29 | The General Hospital Corporation | DNA encoding procine interleukin-10 |
US5958403A (en) * | 1992-02-28 | 1999-09-28 | Beth Israel Hospital Association | Methods and compounds for prevention of graft rejection |
EP1488805A2 (en) | 1992-04-07 | 2004-12-22 | The Regents of the University of Michigan | CD28 pathway immunoregulation |
US5747034A (en) * | 1992-07-09 | 1998-05-05 | Chiron Corporation | Methods and materials for the induction of T cell anergy |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5773253A (en) | 1993-01-22 | 1998-06-30 | Bristol-Myers Squibb Company | MYPPPY variants of CTL A4 and uses thereof |
JPH08511166A (ja) | 1993-06-04 | 1996-11-26 | アメリカ合衆国 | T細胞の増殖を選択的に刺激する方法 |
AU7107794A (en) | 1993-06-10 | 1995-01-03 | Regents Of The University Of Michigan, The | Cd28 pathway immunosuppression |
JP2991499B2 (ja) | 1993-09-02 | 1999-12-20 | トラスティーズ・オブ・ダートマス・カレッジ | 抗gp39抗体およびその用途 |
WO1995015159A1 (fr) * | 1993-12-01 | 1995-06-08 | Sankyo Company, Limited | Inhibiteur de la production de cytokines inflammatoires, contenant un derive polyprenyle comme principe actif |
US5683693A (en) | 1994-04-25 | 1997-11-04 | Trustees Of Dartmouth College | Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40 |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
CA2191586A1 (en) | 1994-06-03 | 1995-12-14 | Carl H. June | Methods for selectively stimulating proliferation of t cells |
WO1995034320A2 (en) | 1994-06-07 | 1995-12-21 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
US5634055A (en) * | 1994-09-27 | 1997-05-27 | Bidplus, Inc. | Method for selecting assignments |
WO1996014865A1 (en) | 1994-11-10 | 1996-05-23 | Repligen Corporation | Methods for inhibiting graft versus host disease in bone marrow transplantation |
US5876950A (en) | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
US5993800A (en) * | 1995-06-05 | 1999-11-30 | Bristol-Myers Squibb Company | Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US6750334B1 (en) * | 1996-02-02 | 2004-06-15 | Repligen Corporation | CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor |
WO1997034633A1 (en) * | 1996-03-20 | 1997-09-25 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
JPH1067653A (ja) * | 1996-06-17 | 1998-03-10 | Eisai Co Ltd | 関節疾患治療剤 |
US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
KR19980066046A (ko) | 1997-01-18 | 1998-10-15 | 정용훈 | 고역가의 CTLA4-Ig 융합단백질 |
US20030219863A1 (en) * | 1997-01-31 | 2003-11-27 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
ZA98533B (en) * | 1997-01-31 | 1999-07-22 | Bristol Myers Squibb Co | Soluble CTLA4 mutant molecules and uses thereof. |
EP1009432A4 (en) | 1997-06-11 | 2004-07-07 | Us Navy | COMPOSITION AND METHOD FOR PREVENTING GRAFT REJECTS OR OTHER NON-ADAPTIVE T-LYMPHOCYTE IMMUNE RESPONSES |
EP0947524A1 (en) * | 1998-03-30 | 1999-10-06 | Upither B.V. | Novel peptides for the treatment of autoimmune diseases |
ES2205792T3 (es) * | 1998-04-03 | 2004-05-01 | Osiris Therapeutics, Inc. | Celulas madre mesenquimatosas como inmunosupresores. |
EP1082124A1 (en) * | 1998-06-05 | 2001-03-14 | Supergen, Inc. | Compositions comprising methotrexate and pentostatin for treating rheumatoid arthritis |
JP2000086519A (ja) * | 1998-09-17 | 2000-03-28 | Mitsui Chemicals Inc | 抗リウマチ薬効果増強剤 |
IL126681A0 (en) | 1998-10-21 | 1999-08-17 | Opperbas Holding Bv | Treatment of trauma-related conditions |
US6040292A (en) * | 1999-06-04 | 2000-03-21 | Celtrix Pharmaceuticals, Inc. | Methods for treating diabetes |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
AU2001264936A1 (en) | 2000-05-23 | 2001-12-03 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the ctla4 gene |
DK1248802T3 (da) | 2000-05-26 | 2004-11-15 | Bristol Myers Squibb Co | Oplöselige CTLA4-mutantmolekyler og anvendelser deraf |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
KR20030007899A (ko) * | 2000-06-09 | 2003-01-23 | 브리스톨-마이어스스퀴브컴파니 | 림프구성 신호의 차단 및 lfa-1 매개 접착의 차단을통한 세포-매개 면역 반응의 조절 방법 |
TWI311564B (en) * | 2000-07-03 | 2009-07-01 | Bristol Myers Squibb Compan | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US20040022787A1 (en) * | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
HUP0303930A3 (en) * | 2001-01-26 | 2012-09-28 | Univ Emory | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
DK1397153T3 (da) * | 2001-05-23 | 2008-05-26 | Bristol Myers Squibb Co | Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler |
-
2001
- 2001-07-02 TW TW090116137A patent/TWI311564B/zh not_active IP Right Cessation
- 2001-07-02 CN CNB018122299A patent/CN1318086C/zh not_active Expired - Lifetime
- 2001-07-02 EP EP18158752.8A patent/EP3384924A1/en not_active Withdrawn
- 2001-07-02 AT AT01952420T patent/ATE401909T1/de active
- 2001-07-02 JP JP2002507889A patent/JP2004517806A/ja active Pending
- 2001-07-02 ES ES08001340.2T patent/ES2667203T3/es not_active Expired - Lifetime
- 2001-07-02 TW TW097137769A patent/TWI322153B/zh not_active IP Right Cessation
- 2001-07-02 KR KR1020087019039A patent/KR100895552B1/ko active Protection Beyond IP Right Term
- 2001-07-02 PT PT01952420T patent/PT1372696E/pt unknown
- 2001-07-02 KR KR1020087005505A patent/KR100864120B1/ko active IP Right Grant
- 2001-07-02 KR KR10-2003-7000018A patent/KR20030017606A/ko active Application Filing
- 2001-07-02 MX MXPA02012603A patent/MXPA02012603A/es active IP Right Grant
- 2001-07-02 CZ CZ20024261A patent/CZ303959B6/cs not_active IP Right Cessation
- 2001-07-02 TR TR2018/07700T patent/TR201807700T4/tr unknown
- 2001-07-02 RU RU2003103098/14A patent/RU2287340C2/ru active
- 2001-07-02 WO PCT/US2001/021204 patent/WO2002002638A2/en active Application Filing
- 2001-07-02 ES ES01952420T patent/ES2310557T3/es not_active Expired - Lifetime
- 2001-07-02 US US09/898,195 patent/US7455835B2/en not_active Expired - Lifetime
- 2001-07-02 MY MYPI20013159A patent/MY137552A/en unknown
- 2001-07-02 PL PL365942A patent/PL207534B1/pl unknown
- 2001-07-02 CA CA002413190A patent/CA2413190C/en not_active Expired - Lifetime
- 2001-07-02 BR BR0112104-9A patent/BR0112104A/pt not_active Application Discontinuation
- 2001-07-02 HU HU0900660A patent/HU227669B1/hu unknown
- 2001-07-02 PL PL389002A patent/PL212205B1/pl unknown
- 2001-07-02 AU AU7317401A patent/AU7317401A/xx active Pending
- 2001-07-02 DK DK01952420T patent/DK1372696T3/da active
- 2001-07-02 EP EP08001340.2A patent/EP1935427B1/en not_active Expired - Lifetime
- 2001-07-02 AU AU2001273174A patent/AU2001273174B2/en not_active Expired
- 2001-07-02 IL IL15359301A patent/IL153593A0/xx unknown
- 2001-07-02 RS YUP-1011/02A patent/RS50811B/sr unknown
- 2001-07-02 EP EP01952420A patent/EP1372696B1/en not_active Expired - Lifetime
- 2001-07-02 DK DK08001340.2T patent/DK1935427T3/en active
- 2001-07-02 EP EP10184596.4A patent/EP2281568A3/en not_active Withdrawn
- 2001-07-02 SK SK1774-2002A patent/SK287940B6/sk not_active IP Right Cessation
- 2001-07-02 EE EEP200300004A patent/EE05378B1/xx active Protection Beyond IP Right Term
- 2001-07-02 SI SI200120046A patent/SI21078A/sl not_active IP Right Cessation
- 2001-07-02 AR ARP010103156A patent/AR035037A1/es active IP Right Grant
- 2001-07-02 SI SI200130864T patent/SI1372696T1/sl unknown
- 2001-07-02 PT PT80013402T patent/PT1935427T/pt unknown
- 2001-07-02 HU HU0301727A patent/HU226847B1/hu active Protection Beyond IP Right Term
- 2001-07-02 SI SI200131067T patent/SI1935427T1/en unknown
- 2001-07-02 CA CA2630062A patent/CA2630062C/en not_active Expired - Lifetime
- 2001-07-02 UY UY26815A patent/UY26815A1/es not_active Application Discontinuation
- 2001-07-02 LT LTEP08001340.2T patent/LT1935427T/lt unknown
- 2001-07-02 DE DE60135029T patent/DE60135029D1/de not_active Expired - Lifetime
- 2001-11-14 PE PE2001001131A patent/PE20020772A1/es not_active Application Discontinuation
-
2002
- 2002-12-06 BG BG107362A patent/BG66024B1/bg unknown
- 2002-12-11 ZA ZA2002/10058A patent/ZA200210058B/en unknown
- 2002-12-23 IL IL153593A patent/IL153593A/en active IP Right Grant
- 2002-12-27 NO NO20026264A patent/NO20026264L/no not_active Application Discontinuation
-
2003
- 2003-01-02 IS IS6667A patent/IS2834B/is unknown
- 2003-01-07 LT LT2003002A patent/LT5063B/lt not_active IP Right Cessation
- 2003-02-03 LV LVP-03-08A patent/LV12993B/en unknown
- 2003-02-03 HR HRP20030071AA patent/HRP20030071B1/hr not_active IP Right Cessation
-
2004
- 2004-02-25 HK HK04101364.2A patent/HK1058486A1/xx not_active IP Right Cessation
-
2008
- 2008-05-09 AR ARP080101975A patent/AR066511A2/es unknown
- 2008-10-21 CY CY20081101167T patent/CY1109786T1/el unknown
- 2008-11-05 CY CY2008017C patent/CY2008017I2/el unknown
-
2010
- 2010-03-05 BG BG110611A patent/BG66454B1/bg unknown
- 2010-04-22 NO NO20100580A patent/NO20100580L/no not_active Application Discontinuation
- 2010-04-22 NO NO20100579A patent/NO20100579L/no unknown
- 2010-04-27 HU HUS1000008C patent/HUS1000008I1/hu unknown
-
2018
- 2018-05-23 CY CY20181100546T patent/CY1120577T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS2834B (is) | Aðferðir til þess að meðhöndla gigtarsjúkdóma með því að nota leysanlega CTLA4-sameind | |
NO2022001I1 (no) | Pazopanib | |
UY26249A1 (es) | Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127 | |
DK1615952T3 (da) | Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler | |
DE60314500D1 (de) | Diaminopyrimidine und deren verwendung als angiogenesehemmer | |
IL184617A (en) | Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody | |
MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
CY1110259T1 (el) | Ανοσορυθμιστης | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
PT1347971E (pt) | Inibidores tiazolilicos de tirosina-cinases da familia tec | |
EP1912674A4 (en) | BIS SPECIFIC SINGLE CHAIN FV ANTIBODY MOLECULES AND METHOD OF USE THEREOF | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
BRPI0509660A (pt) | compostos de beta-carbolina de utilidade no tratamento de doenças inflamatórias | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
EA200400235A1 (ru) | Комбинированная терапия для лечения рака | |
DK1572087T3 (da) | Antistoffer med cancerantigen TMEFF2 og anvendelser deraf | |
DE602004024921D1 (de) | Zusammensetzungen und verfahren zur behandlung von tumoren hämatopoetischen ursprungs | |
DK1895017T3 (da) | Anvendelse af A33-antigener og JAM-IT | |
HK1154904A1 (zh) | 天然 抗體及其抑制劑 | |
DE60127131D1 (de) | Tricyclische imidazopyridine | |
EA200801211A1 (ru) | Производные 9-хлор-15-простагландина, способ их получения и использования в лекарственных препаратах | |
DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
DE60321355D1 (de) | Verfahren zur reproduzierung von pleuromutilinen |